Avalo Therapeutics (AVTX) vs Phathom Pharmaceuticals (PHAT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Avalo Therapeutics (AVTX) has outperformed Phathom Pharmaceuticals (PHAT) over the past year, losing 62.1% versus a loss of 68.9%. Over five years, PHAT leads with a -76.5% price change compared with -99.9% for AVTX. Avalo Therapeutics is the larger company by market cap ($390.9 million vs $378.8 million), about 1.0 times the size, while Phathom Pharmaceuticals is growing revenue faster (+216.9% vs -86.6%).
Phathom Pharmaceuticals converts more of its revenue into profit, with a net margin of -126.3% versus -132642.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTX | PHAT |
|---|---|---|
| Share price | $6.76 | $4.66 |
| Market cap | $390.88M | $378.82M |
| 1-day change | +0.15% | -8.27% |
| YTD return | -62.78% | -71.91% |
| 1-year return | -62.09% | -68.93% |
| 5-year return | -99.89% | -76.46% |
| Forward P/E | — | 5.18 |
| EPS (TTM) | $-2.26 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $59.00K | $175.11M |
| Revenue growth (YoY) | -86.62% | +216.93% |
| Net income (latest FY) | $-78.26M | $-221.25M |
| Gross margin | — | 87.09% |
| Operating margin | -123601.69% | -91.36% |
| Net margin | -132642.37% | -126.35% |
| 52-week high | $24.27 | $18.31 |
| 52-week low | $6.53 | $4.62 |
| Distance from 52-week high | -72.15% | -74.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +414.79% | +321.67% |
| Average volume | 1.80M | 1.45M |
| Shares outstanding | 57.82M | 81.29M |
| Employees | 33 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Phathom Pharmaceuticals is more profitable, keeping -126.3 cents of every revenue dollar as net income versus -132642.4 cents for Avalo Therapeutics.
- Phathom Pharmaceuticals grew revenue faster in its latest fiscal year (+216.93% vs -86.62%).
About Avalo Therapeutics
AVTX stock →Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Phathom Pharmaceuticals
PHAT stock →Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Health Care · Biotechnology: Pharmaceutical Preparations · 371 employees
AVTX vs PHAT FAQ
Which is bigger, Avalo Therapeutics or Phathom Pharmaceuticals?
Avalo Therapeutics (AVTX) is larger, with a market capitalization of $390.88M compared with $378.82M for Phathom Pharmaceuticals (PHAT).
Which stock has performed better over the past year, AVTX or PHAT?
AVTX returned -62.09% over the past 12 months, compared with -68.93% for PHAT (price return, excluding dividends). Past performance does not predict future results.
Are Avalo Therapeutics and Phathom Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.